Recombinant human erythropoietin in the treatment of anemic patients with hematological malignancies

Annals of Hematology

Volumn 80, Issue 6, 2001, Pages 319-329

  Kasper, C ^a,b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Anemia; Efficacy; Erythropoietin; Hematological malignancies; Tolerability

Indexed keywords

AMPHOTERICIN B; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACARBAZINE; DOXORUBICIN; ERYTHROPOIETIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; INTERLEUKIN 1; PLACEBO; PREDNISONE; PROCARBAZINE; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR; VINBLASTINE; VINCRISTINE;

ALGORITHM; ALLOGENIC BONE MARROW TRANSPLANTATION; ANEMIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TRANSFUSION; BONE DISEASE; CANCER CLASSIFICATION; DRUG COST; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; ERYTHROPOIESIS; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEADACHE; HEART FAILURE; HEMATOLOGIC DISEASE; HEMATOLOGICAL PARAMETERS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; REVIEW; SPLENOMEGALY; THROMBOPHLEBITIS;

ANEMIA; CLINICAL TRIALS; ERYTHROPOIETIN, RECOMBINANT; HEMATOLOGIC NEOPLASMS; HUMANS;

EID: 0034960293     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770100333     Document Type: Review

References (110)

1. Erythropoietin for anemia in cancer patients
2. Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor
3. Recombinant human erythropoietin and the anemia of multiple myeloma
4. Inadequate erythropoietin response to anemia: Definition and clinical relevance
5. Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines
6. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia
7. Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy
8. Prediction of response to optimize outcome of treatment with erythropoietin
9. Recombinant human erythropoietin for the treatment of anemia in chronic myelogenous leukemia
10. The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin
11. 1
12. Effect of blood transfusions on colonic malignancy recurrence rate
13. Regulation of transferrin receptor expression and ferritin content in human mononuclear phagocytes: Coordinate upregulation by iron transferrin and downregulation by interferon-gamma
14. The anaemia of chronic disorders
15. Recombinant human erythropoietin treatment in cisplatin-associated anemia: A randomized, double-blind trial with placebo
16. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy
17. The anemia of chronic disease: Spectrum of associated diseases in a series of unselected hospitalized patients
18. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response
19. Subcutaneous erythropoietin for the treatment of refractory anemia in hematological disorders. Results of a phase I/II clinical trial
20. The functional assessment of cancer therapy-anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue
21. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation
22. The pharmacokinetics and pharmacodynamics of epoetin-alpha once weekly versus epoetin-alpha three times weekly
23. Identifying hemoglobin level for optimal quality of life: Results of an incremental analysis
24. Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia
25. The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy
26. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia
27. Quality-of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
28. Correlation between neopterin, interferon-gamma and haemoglobin in patients with haematological disorders
29. Adverse consequences of blood transfusion: Quantitative risk estimates
30. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin
31. Treatment of anemia in low risk myelodysplastic syndromes with granulocyte-macrophage colony stimulating factor plus recombinant human erythropoietin
32. A meta-analysis on the safety of Epoetin-β therapy in cancer patients
33. Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: Role of cytokines and monitoring of erythropoiesis
34. Recombinant human erythropoietin in the treatment of cancer-related anaemia
35. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production
36. Decreased affinity and number of transferrin receptors on erythroblasts in the anemia of rheumatoid arthritis
37. Association between immune activation, changes of iron metabolism and anaemia in patients with HIV infection
38. Macrophage control of normal and leukemic erythropoiesis: Identification of the macrophage-derived erythroid suppressing activity as interleukin-1 and the mediator of its in vivo action as tumor necrosis factor
39. Epoetin alfa for the treatment of the anemia of multiple myeloma
40. Subcutaneous recombinant human erythropoietin for the treatment of anemia in myelodysplastic syndromes
41. R-Hu erythropoietin treatment increases efficacy of neoadjuvant radiochemotherapy and improves cancer free survival with oral squamous cell carcinoma: A 17 month follow up
42. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
43. Transfusion Medicine. Blood transfusion
44. Recombinant erythropoietin and blood transfusions in cancer chemotherapy-induced anemia
45. Chemotherapy-induced anemia in adults: Incidence and treatment
46. Blood transfusion-modulated tumor recurrence: First results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery
47. Efficiency of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies
48. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: Results from randomized phase II study and long-term follow-up of 71 patients
49. Prediction of response to recombinant human erythropoietin (r-HuEPO/epoetin-α) therapy in cancer patients
50. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open label follow-up studies
51. Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodsyplastic syndromes
52. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys
53. Noninfectious complications of blood transfusion
54. In vivo suppression of erythropoiesis by tumor necrosis factor-α (TNF-α): Reversal with exogenous erythropoietin (EPO)
55. In vivo hematopoietic effects of recombinant interleukin-1α in mice: Stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and suppression with erythropoietin
56. Recombinant human erythropoietin in the treatment of cancer-related anaemia
57. Reduced blood transfusions requirements after allogeneic bone marrow transplantation: Results of randomized, double-blind study with high-dose erythropoietin
58. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: A prospective randomized, double-blind placebo-controlled multicenter study
59. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States
60. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin
61. Decrease in frequency of transfusion fatalities
62. A controlled trial of recombinant human erythropoietin after bone marrow transplantation
63. Efficacy and quality of life of epoetin alfa in a double-blind, placebo-controlled multicenter study of cancer patients receiving non-platinum containing chemotherapy
64. Possible relationship of hemoglobin levels with survival in anemic cancer patients receiving chemotherapy
65. Erythropoietin treatment of anemia associated with multiple myeloma
66. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors
67. Prediction of response to erythropoietin treatment in chronic anemia of cancer
68. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin
69. Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon
70. Progress in understanding the pathogenesis of the anemia of chronic disease
71. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon
72. Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin
73. Decreased erythropoietin response in patients with the anemia of cancer
74. Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia
75. Recombinant human erythropoietin in patients with myelodysplastic syndromes and myelofibrosis
76. Erythropoietin treatment of anaemia associated with lymphoproliferative disorders
77. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: Evidence for in vivo synergy
78. The differentiation of delayed serologic and delayed hemolytic transfusion reactions: Incidence, long-term serologic findings, and clinical significance
79. Pathophysiology of cancer related anaemia
80. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study
81. What are cancer patients willing to pay for prophylactic epoetin alfa?
82. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration
83. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - A randomized multicenter study
84. Effective treatment of disease-related anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin
85. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients
86. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury
87. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens
88. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders
89. Tumor necrosis factor-alpha and hematopoietic progenitors: Effects of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell line K562, HL60 and HEL cells
90. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO)
91. The use of r-Hu Epo in the treatment of anaemia related to myelodysplasia (MDS)
92. Combination of granulocyte-macrophage colony-stimulating factor (GM-CSF) and erythropoietin (EPO) for the treatment of advanced non-responsive chronic lymphocytic leukemia
93. Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anaemias
94. The risk of transfusion-transmitted viral infections
95. The risk of an overt hemolytic transfusion reaction following the use of an immediate spin cross-match
96. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect
97. Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma
98. The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study
99. Recombinant human granulocyte-macrophage colony stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes
100. Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: Results of a prospective controlled randomized trial
101. Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes
102. Reports of 355 transfusion-associated deaths: 1976 through 1985
103. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer
104. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome
105. Deleterious clinical effects of transfusion-associated immunomodulation: Fact or fiction?
106. Inhibition of erythropoietin production in vitro by human interferon gamma
107. Tumor oxygenation: Characterization and clinical implications
108. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: A clinical and erythrokinetic assessment
109. rhEPO in the treatment of the myelodysplastic syndromes
110. Erythropoietin - Einsatz in Hämatoonkologie und Strahlentherapie